{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT00543959: Phase 2 Interventional Terminated Diabetes Mellitus Type 2
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-0533 is a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus. In comparison with PPARγ full agonists, MK-0533 displayed diminished maximal activity (partial agonism) in cell-based transcription activation assays and attenuated gene signatures in adipose tissue. MK-0533 exhibited comparable efficacy to rosiglitazone and pioglitazone in vivo. However, with regard to the induction of untoward events, MK-0533 displayed no cardiac hypertrophy, attenuated increases in brown adipose tissue, minimal increases in plasma volume, and no increases in extracellular fluid volume in vivo. MK-0533 was teste in phase II clinical trials but future development was discontinued.
Status:
Investigational
Source:
NCT00431782: Phase 2 Interventional Completed Atrial Fibrillation
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Dazmegrel [UK 38485] is a thromboxane synthetase inhibitor which was undergoing development in the treatment of thrombosis, ischaemic heart disease, arrhythmias and asthma. Pfizer were conducting phase II studies in Denmark and the UK, phase I studies in Germany and Italy, and preclinical studies in France. Later this research was discontinued.
Status:
Investigational
Source:
NCT01344148: Not Applicable Interventional Unknown status AIDS
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02864888: Phase 3 Interventional Not yet recruiting Brain Stem Glioma
(2027)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Antineoplaston A10 has been used in trials studying the treatment of glioma, sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer, among others.
Status:
Investigational
Source:
NCT00219609: Phase 2/Phase 3 Interventional Completed Ejaculation
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
UK-390957 is a selective serotonin reuptake inhibitor (SSRI) that was in phase II/III development in the USA, European Union and other territories with Pfizer, for the treatment of Premature ejaculation. UK-390957 represented a major development in sexual medicine, and offered patients the convenience of on-demand dosing, significant improvements in IELT, ejaculatory control, and sexual satisfaction with minimal adverse effects. However development of UK-390957 was discontinued.
Status:
Investigational
Source:
NCT01039844: Phase 1 Interventional Terminated Melanoma
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
KETAZOCINE, a benzomorphan derivative, is a kappa opioid receptor agonist. It is used in opioid receptor research.
Status:
Investigational
Source:
NCT01561456: Phase 2 Interventional Completed Non-small-cell Lung Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Picropodophyllin (also known as picropodophyllotoxin (PPP)), an orally active insulin-like growth factor 1 receptor (IGF1R) inhibitor that exhibits no activity at the insulin receptor, FGFR, PDGFR or EGFR. Picropodophyllin possesses antineoplastic activity. PPP is currently tested as an orally administrated single agent treatment in an open-label combined Phase I/II clinical study in advanced cancer patients with solid tumors which progress in spite of several lines of treatment. In addition, it effectively inhibits rhambodmyosarcomas tumor proliferation and metastasis in vitro and in an animal model.
Status:
Investigational
Source:
NCT00003328: Phase 3 Interventional Completed Head and Neck Cancer
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Porfiromycin is an N-methyl derivative of the antineoplastic antibiotic mitomycin-C initially isolated from Streptomyces ardus. Upon administration, the drug undergoes chemical or enzymatic reduction, followed by spontaneous loss of the tertiary methoxy (hydroxyl) group and formation of an aromatic indole system. Thus activated, porfiromycin generates oxygen radicals and alkylates DNA, producing interstrand cross-links and single-strand breaks at guanosine residues. Porfiromycin was tested in phase III for head and neck carcinoma, however, its development was terminated.
